Kamada (KMDA) Long-Term Deferred Tax (2018 - 2025)
Kamada (KMDA) posted quarterly Long-Term Deferred Tax of $1.7 million for Q4 2025, up 238.32% year-on-year from $488000.0 in Q4 2024, and up 238.32% on a QoQ basis from $488000.0 in Q4 2024.
Kamada (KMDA) Long-Term Deferred Tax (2018 - 2025) Analysis & Trends
Kamada (KMDA) has reported Long-Term Deferred Tax for 5 consecutive years, with $1.7 million the latest figure, recorded in Q4 2025.
- Quarterly Long-Term Deferred Tax rose 238.32% year-over-year to $1.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.7 million (up 238.32% YoY) and the FY2025 annual result came in at $1.7 million, up 238.32% from the prior year.
- Long-Term Deferred Tax improved to $1.7 million in Q4 2025 per KMDA's latest filing, from $488000.0 in the prior quarter.
- Over the last five years, Long-Term Deferred Tax for KMDA reached as high as $1.7 million in Q4 2025 and fell as low as $488000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Kamada | 401.22 Mn | 328.07 Mn | 19.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.65 Mn |
| Dec 31, 2024 | 488,000.00 |
| Sep 30, 2020 | 298,000.00 |
| Mar 31, 2020 | 421,000.00 |
| Dec 31, 2019 | 1.31 Mn |
| Dec 31, 2018 | 2.05 Mn |